{"id":"anti-cd123-car-nk-cells","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL4757479","moleculeType":"Unknown","molecularWeight":"483.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Chimeric antigen receptor T cells engineered to recognize and kill cancer cells expressing CD123.","oneSentence":"CAR-T cell therapy targeting CD123","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:34:15.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT06690827","phase":"PHASE1","title":"Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN","status":"RECRUITING","sponsor":"Chongqing Precision Biotech Co., Ltd","startDate":"2024-11-13","conditions":"AML (Acute Myeloid Leukemia), BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)","enrollment":30},{"nctId":"NCT03203369","phase":"PHASE1","title":"Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN","status":"TERMINATED","sponsor":"Cellectis S.A.","startDate":"2017-06-28","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Anti-CD123 CAR NK cells","genericName":"Anti-CD123 CAR NK cells","companyName":"Chongqing Precision Biotech Co., Ltd","companyId":"chongqing-precision-biotech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CAR-T cell therapy targeting CD123 Used for Acute myeloid leukemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}